IXICO
IXICO plc is a UK clinical research firm that provides neuroimaging and digital biomarker analytics to biopharmaceutical firms conducting clinical trials into neurological diseases such as Alzheimer's disease (AD) and Huntington's disease (HD).
 | |
| Company type | Public limited company |
|---|---|
| LSE:IXI | |
| Industry | Data analytics for clinical research |
| Founded | 2004 |
| Founders | Professors Derek Hill, Daniel Rueckert, David Hawkes and Jo Hajnal |
| Headquarters | London , United Kingdom |
Area served | Worldwide |
Key people | Charles Spicer (Chairman) Giulio Cerroni (CEO) |
| Website | https://ixico.com/ |
IXICO plc is a UK clinical research firm that provides neuroimaging and digital biomarker analytics to biopharmaceutical firms conducting clinical trials into neurological diseases such as Alzheimer's disease (AD) and Huntington's disease (HD).
Company history
[edit]IXICO was incorporated in 2004[1] as a spin-out from three London academic institutions: Imperial College London, University College London and King's College London.[2] The initial 3-year research project was called 'Information eXtraction from Images' (hence the IXI name), and funded by the UK e-science core and other industry partners.[3]
In October 2013, IXICO entered the Alternative Investment Market (AIM) of the London Stock Exchange through a reverse takeover of defunct pharmaceutical drug company Phytopharm.[4]
Phytopharm
[edit]Phytopharm was a British pharmaceutical company, incorporated on 28 November 1995. Briefly known as Lawnhale, it changed its name to Phytopharm in March 1996[5] and listed on the London Stock Exchange on 25 April of the same year (LSE:PYM).[6] It announced plans for a secondary listing on NASDAQ in 2004 (NASDAQ:PHYOF).[7] By 2012, the Phytopharm group consisted of a parent company, Phytopharm plc, a wholly owned trading subsidiary, Phytotech Limited, and a dormant subsidiary, Phytodevelopments Limited.[8]
Amongst other activity, Phytopharm raised funds for research into treatment of Parkinson's disease (PD) from sources including the Michael J Fox Foundation,[9] but the company collapsed in 2013 following the failure of its main PD drug (Cogane) during clinical trials.[10] Its shares were suspended from trading on 20 May 2013.[11][12]
References
[edit]- ^ Chesters, Laura (24 September 2013). "Independent". Retrieved 30 November 2018.
- ^ Nair, Praseeda (8 August 2006). "growthbusiness.co.uk". Retrieved 30 November 2018.
- ^ "What is IXI?". www0.cs.ucl.ac.uk. Retrieved 30 November 2018.
- ^ "Phytopharm plc to be renamed IXICO plc on admission - London Stock Exchange". www.londonstockexchange.com. Retrieved 30 November 2018.
- ^ "IXICO PLC - Overview (free company information from Companies House)". beta.companieshouse.gov.uk. Retrieved 4 December 2018.
- ^ "Resources".
- ^ "Phytopharm turns to Nasdaq in search for US investors". The Independent. Retrieved 4 December 2018.
- ^ "Phytopharm PLC Preliminary Results". ADVFN. Retrieved 4 December 2018.
- ^ "Phytopharm turns to Nasdaq in search for US investors". The Independent. Retrieved 4 December 2018.
- ^ "Cogane for Parkinson's Shows No Benefit over Placebo in Clinical Trial". The Michael J. Fox Foundation for Parkinson's Research | Parkinson's Disease. Retrieved 4 December 2018.
- ^ "Phytopharm (PYM) Share Price". ADVFN. Retrieved 4 December 2018.
- ^ "Phytopharm suspends shares pending acquisition | Business Weekly | Technology News | Business news | Cambridge and the East of England". www.businessweekly.co.uk. Retrieved 4 December 2018.
